These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32772926)

  • 1. Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery.
    Li S; Zhu Z
    J Ovarian Res; 2020 Aug; 13(1):91. PubMed ID: 32772926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrioid Carcinoma of the Ovary: Outcomes Compared to Serous Carcinoma After 10 Years of Follow-Up.
    Bouchard-Fortier G; Panzarella T; Rosen B; Chapman W; Gien LT
    J Obstet Gynaecol Can; 2017 Jan; 39(1):34-41. PubMed ID: 28062021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
    Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
    Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
    Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O
    Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Ceppi L; Grassi T; Galli F; Buda A; Aletti G; Lissoni AA; Adorni M; Garbi A; Colombo N; Bonazzi C; Landoni F; Fruscio R
    Gynecol Oncol; 2021 Jan; 160(1):64-70. PubMed ID: 33077259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
    Vogel TJ; Goodman MT; Li AJ; Jeon CY
    Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
    Peres LC; Cushing-Haugen KL; Köbel M; Harris HR; Berchuck A; Rossing MA; Schildkraut JM; Doherty JA
    J Natl Cancer Inst; 2019 Jan; 111(1):60-68. PubMed ID: 29718305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
    Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
    Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of long-term prognostic factors of epithelial ovarian cancer].
    Li MD; Li YJ; Huang YW; Huang H
    Ai Zheng; 2004 Nov; 23(11):1306-10. PubMed ID: 15522179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laparoscopic staging for apparent stage I epithelial ovarian cancer.
    Melamed A; Keating NL; Clemmer JT; Bregar AJ; Wright JD; Boruta DM; Schorge JO; Del Carmen MG; Rauh-Hain JA
    Am J Obstet Gynecol; 2017 Jan; 216(1):50.e1-50.e12. PubMed ID: 27567562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.
    Ayeni TA; Bakkum-Gamez JN; Mariani A; McGree ME; Weaver AL; Haddock MG; Keeney GL; Long HJ; Dowdy SC; Podratz KC
    Gynecol Oncol; 2013 Jun; 129(3):478-85. PubMed ID: 23535279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
    Tang L; Zheng M; Xiong Y; Ding H; Liu FY
    Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
    Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
    Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
    Ma SK; Zhang HT; Sun YC; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and treatment of the epithelial ovarian cancer at the West African Cancer Center of Dakar].
    Dem A; Dieng MM; Ka S; Gaye PM; Diouf D; Gaye-Fall MC
    Bull Cancer; 2013 Feb; 100(2):155-60. PubMed ID: 23407147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
    Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
    J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy, Radiation, or Combination Therapy for Stage III Uterine Cancer.
    Syeda S; Chen L; Hou JY; Tergas AI; Khoury-Collado F; Melamed A; St Clair CM; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Obstet Gynecol; 2019 Jul; 134(1):17-29. PubMed ID: 31188310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.